secwatch.observer — SEC 8-K summary
======================================

Issuer:     Imunon, Inc. (IMNN)
CIK:        0000749647
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001493152-25-022118
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imunon posts Q3 net loss of $3.4M, cash $5.3M; Phase 3 ovarian cancer study enrollment ahead
--------------------------------------------------------------------------------

- Net loss of $3.4M ($1.16/sh) in Q3 2025 vs $4.8M ($3.76/sh) in Q3 2024; operating expenses down 30% to $3.5M.
- Cash and equivalents $5.3M as of Sept 30, 2025; $4.5M raised from warrant exercises and ATM; runway into Q1 2026.
- Phase 3 OVATION 3 study for IMNN-001 in advanced ovarian cancer enrollment exceeding expectations; Phase 2 data showed 13-month OS benefit.
- R&D Day on Nov 10 highlighted investigator optimism and translational data; new data presented at SITC and AACR.
- PlaCCine DNA vaccine platform proof-of-concept data presented; actively seeking partnerships.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/749647/000149315225022118/0001493152-25-022118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/749647/000149315225022118/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-022118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer